The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 16th - August 22nd, 2021.
Alerts this week cover papers from New England Journal of Medicine, European Urology, Journal of Immunotherapy of Cancer, ESMO Open and The Lancet.
Dr Morgan also mentions the FDA approval of Nivolumab in the adjuvant treatment of patients with urothelial carcinoma at risk of recurrence after radical resection, regardless of prior neoadjuvant chemotherapy or PDL1 status.
You can watch Dr Morgan's previous roundup here
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
GIST tumours and soft tissue sarcomas
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
